Zentiva's Tender Offer for APONTIS PHARMA: Minimum Acceptance Requirement Waived

Zentiva has waived the minimum acceptance condition in its voluntary public purchase offer for APONTIS PHARMA AG. The acceptance period ends today, 21 November 2024, at 24:00 CET. So far, about 60% of shares have been tendered. The management and supervisory boards of APONTIS PHARMA recommend shareholders accept the offer.

An investment agreement will lead to the delisting of APONTIS PHARMA shares post-settlement. Paragon, the main shareholder, has a share purchase agreement at EUR 9.00 per share, aligning with the offer price of EUR 10.00. This represents a significant premium compared to the pre-announcement share price.

Market regulatory conditions remain unchanged, and mergers clearance was granted earlier this month. The management believes the offer is attractive given the current market valuation.